Protagenic Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	5.8yrs

Recent management updates

Recent updates

CEO

Protagenic Therapeutics has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Garo Armen	Co-Founder & Executive Chairman of the Board	no data	no data	16.53% $ 477.1k
Robert Stein	Chief Medical Officer & Director	8.8yrs	no data	no data
Timothy Wright	Independent Director	2yrs	no data	no data
Brian Corvese	Independent Director	7.3yrs	US$118.75k	no data
Khalil Barrage	Independent Director	no data	US$243.75k	3.38% $ 97.5k
Jennifer Buell	Independent Director	4.3yrs	no data	no data

5.8yrs

Average Tenure

66yo

Average Age

Experienced Board: PTIX's board of directors are considered experienced (5.8 years average tenure).

Protagenic Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Protagenic Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director

Protagenic Therapeutics, Inc., Annual General Meeting, Nov 23, 2022

Recent updates

Protagenic Therapeutics Receives A Delist Determination Letter from the Nasdaq

New major risk - Financial position

Protagenic Therapeutics, Inc. announced that it expects to receive $1.275 million in funding

Protagenic Therapeutics, Inc. Receives A Deficiency Letter from the Nasdaq Listing Qualifications Regarding Minimum Bid Price Requirement

New minor risk - Shareholder dilution

Protagenic Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Set Forth in Nasdaq Listing Rule 5550(b)(1)

Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial

New major risk - Share price stability

New major risk - Financial position

Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders

Protagenic Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

New major risk - Share price stability

Protagonist Therapeutics, Inc. Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals

Protagenic Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirements Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on The Nasdaq Capital Market

New minor risk - Shareholder dilution

Protagenic Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

New minor risk - Share price stability

Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director

Protagenic Therapeutics, Inc., Annual General Meeting, Nov 23, 2022

Protagenic Therapeutics, Inc. announced delayed annual 10-K filing

Protagenic Therapeutics, Inc's Common Stock Deleted from Other OTC

Protagenic Therapeutics, Inc. has completed a Composite Units Offering in the amount of $13.197 million.

Protagenic Therapeutics, Inc. Announces Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial

Protagenic Therapeutics, Inc. announced that it has received $2 million in funding

Protagenic Therapeutics, Inc. announced that it has received $0.4275 million in funding

Protagenic Therapeutics, Inc. announced that it expects to receive $0.475 million in funding

CEO

Board Members

Average Tenure

Average Age